分组1 - BridgeBio Pharma reported a quarterly loss of $1 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.75, and compared to a loss of $1.31 per share a year ago, indicating a surprise of -34.05% [1] - The company posted revenues of $154.18 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 2.77%, and showing a significant increase from year-ago revenues of $5.88 million [2] - Over the last four quarters, BridgeBio Pharma has surpassed consensus revenue estimates four times, but has only exceeded consensus EPS estimates once [2] 分组2 - The stock has underperformed the market, losing about 11.2% since the beginning of the year, while the S&P 500 has declined by only 0.1% [3] - The current consensus EPS estimate for the coming quarter is -$0.64 on revenues of $173.51 million, and for the current fiscal year, it is -$1.79 on revenues of $900.31 million [7] - The Zacks Industry Rank for Medical - Generic Drugs is currently in the bottom 34% of over 250 Zacks industries, indicating potential challenges for stocks in this sector [8]

Financial Performance - BridgeBio Pharma reported a quarterly loss of $0.95 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.83, representing an earnings surprise of -14.46% [1] - The company posted revenues of $110.57 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 14.95%, compared to revenues of $2.17 million a year ago [2] - Over the last four quarters, BridgeBio Pharma has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - BridgeBio Pharma shares have increased approximately 74% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.6% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.61 on revenues of $136.32 million, and for the current fiscal year, it is -$3.16 on revenues of $466.56 million [7] - The estimate revisions trend for BridgeBio Pharma was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Generic Drugs industry, to which BridgeBio Pharma belongs, is currently ranked in the bottom 36% of over 250 Zacks industries, suggesting potential challenges for stock performance [8]